This site is intended for healthcare professionals
News

Phase III trials show efficacy of EB 1020 in attention-deficit hyperactivity disorder.- Otsuka Pharmaceutical

Read time: 1 mins
Last updated:12th Jun 2020
Published:12th Jun 2020
Condition: Attention Deficit Hyperactivity Disorder
Type: drug
Register free for full access to medthority.com